Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Mar 23, 2022 4:07pm
87 Views
Post# 34539140

RE:RE:Twitter Update

RE:RE:Twitter UpdateThe Arbitration process must be completed by the end of 12 months from filing.  That doesn't mean the Arbitrator would necessarily take that long for the ruling let alone a settlement by the two parties. I think if it s going to arbitration we could see something soon.
From the Dec. 14th tweet:
"Quick update on the arbitration with Shiseido. Things are proceeding on schedule and picking up pace. The next 6-8 weeks will be about filing full pleadings, evidence, witness statements, etc. Having seen their initial Response, we remain confident in the strength of our case."

Eight weeks would have taken until Feb. 14th over a month ago for the "full pleadings, evidence and witness statements".

There is a lot riding on this arbitration. I am not sure what will happen if the ruling goes against Replicel. It may not be a disaster as Shiseido will most likely take RCH-01 to commercialization. I am not sure how that will work for Replicel. Who will have the rights to the procedure? If it goes the other way I think we will see a substantial jump in the valuation of Replicel.
<< Previous
Bullboard Posts
Next >>